Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

Jeffrey M. Riggs(AstraZeneca (Netherlands)), Roland Kolbeck(AstraZeneca (Australia))
Lupus Science & Medicine
April 1, 2018
Cited by 143


Related Papers